DOCSLIB.ORG

EP1776161B1.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EP1776161B1.Pdf (19) TZZ____T (11) EP 1 776 161 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61Q 5/02 (2006.01) A61Q 7/00 (2006.01) 26.10.2016 Bulletin 2016/43 A61Q 19/00 (2006.01) A61K 8/36 (2006.01) A61K 8/362 (2006.01) A61K 8/37 (2006.01) (2006.01) (2006.01) (21) Application number: 05718804.7 A61K 8/39 A61Q 1/02 A61Q 5/06 (2006.01) A61K 8/64 (2006.01) A61Q 5/12 (2006.01) A61Q 11/00 (2006.01) (22) Date of filing: 25.04.2005 A61K 8/81 (2006.01) A61Q 19/06 (2006.01) A61Q 19/08 (2006.01) A61K 8/97 (2006.01) A61K 8/42 (2006.01) A61K 8/49 (2006.01) A61Q 5/00 (2006.01) A61K 8/73 (2006.01) (86) International application number: PCT/IB2005/051344 (87) International publication number: WO 2005/102266 (03.11.2005 Gazette 2005/44) (54) COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER KOSMETISCHE ODER DERMOPHARMAZEUTISCHE ZUSAMMENSETZUNG MIT MINDESTENS EINEM UDP-GLUCURONOSYL-TRANSFERASE (UGT) ENZYM-INDUKTOR COMPOSITION COSMETIQUE OU DERMOPHARMACEUTIQUE COMPRENANT AU MOINS UN INDUCTEUR D’ENZYMES UDP-GLUCURONOSYLTRANSFERASES (UGT) (84) Designated Contracting States: • PATENT ABSTRACTS OF JAPAN vol. 2000, no. DE ES FR GB IT 14, 5 March 2001 (2001-03-05) & JP 2000 319154 A(NIPPON MENAADEKESHOHIN KK; ICHIMARU (30) Priority: 26.04.2004 FR 0404408 PHARCOS CO LTD), 21 November 2000 (2000-11-21) (43) Date of publication of application: • DATABASE WPI Derwent Publications Ltd., 25.04.2007 Bulletin 2007/17 London, GB; AN 2001-481491 XP002309671 CHEOUNG J H ET AL.: "Chrysin 7-o-crotonate, its (73) Proprietor: Sederma S.A.S. producing method and composition useful for 78612 Le Perray-en-Yvelines Cedex (FR) hair growth tonic" & KR 2001 009 474 A (CHEOUNG J H, KIM P K) 5 February 2001 (72) Inventors: (2001-02-05) •LINTNER,Karl • ANONYMOUS: "Nutrasport Testroxin Gel" F-06500 Menton (FR) INTERNET ARTICLE, [Online] pages 1-2, • MAS, CHAMBERLIN, Claire XP002309667 Global-Nutrition-Inc. Retrieved F-78460 Chevreuse (FR) from the Internet: URL:http://www.bodybuilding-supplements-fo (56) References cited: r-you.com/nutrasport/testroxin-gel.htm> -& EP-A- 1 300 138 WO-A-00/67767 INTERNET ARTICLE, [Online] XP002312910 WO-A-2004/089392 DE-A- 10 009 424 Retrieved from the Internet: FR-A- 2 594 336 FR-A- 2 778 663 URL:http://web.archive.org/web/*/http://ww FR-A- 2 802 413 FR-A- 2 836 042 w.bodybuilding-supplements-for-you.com/nut rasport/testroxin-gel.htm> Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 776 161 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 1 776 161 B1 • INTERNATIONAL ANTIAGING SYSTEMS: • DATABASE EMBASE [Online] ELSEVIER "ESTROGEN BLOCKERS" INTERNET ARTICLE, SCIENCE PUBLISHERS, AMSTERDAM, NL; 2002, [Online] pages 1-2, XP002309668 Retrieved from WALLE U K ET AL: "Induction of human the Internet: UDP-glucuronosyltransferase UGT1A1 by URL:http://www.antiaging-systems.com/a2z/e flavonoids - Structural requirements" strogenblock.htm> XP002309670 Database accession no. • AHN M-R, ET AL.: "Antioxidant activity and EMB-2002159263 & DRUG METABOLISM AND constituents of propolis collected in various DISPOSITION 2002 UNITED STATES, vol. 30, no. areas of Korea" JOURNAL OF AGRICULTURAL 5, 2002, pages 564-569, ISSN: 0090-9556 AND FOOD CHEMISTRY, vol. 52, 11 February 2004 (2004-02-11), pages 7286-7292, XP002309669 AMERICAN CHEMICAL SOCIETY 2 EP 1 776 161 B1 Description SUMMARY OF THE INVENTION 5 [0001] The invention concerns a new cosmetic or dermopharmaceutical composition to protect and/or enhance the state of the skin and prevent and/or treat imperfections of the skin. BACKGROUND OF THE INVENTION 10 [0002] Cosmetic products that temporarily improve the appearance of the skin by masking the irregularities with an opaque cosmetic film are available. This invention proposes an effective alternative to the use of those masking cosmetic products to prevent and/or treat skin that has aged and/or is subject to environmental aggression. [0003] Throughout life, each individual is subject to exposure to sunlight and air pollution either occasionally or to multiple and/or extreme exposures. The skin continuously suffers aggression from numerous extrinsic but also intrinsic 15 factors. The extrinsic factors include ultraviolet radiation (mainly linked to exposure to the sun: sunlight-induced aging), environmental pollution and atmospheric pollution, but also wind, heat, low relative humidity levels, contact with household surfactants and other chemicals, abrasives, smoking, alcohol, drugs, diet, stress, mechanical stress, severe atmospheric conditions and so on. The intrinsic factors include chronological aging and the other biochemical changes in the skin. The following may also be cited: hormonal upheavals, fatigue, acne, obesity, tanning, diets, disease, for example, 20 hyperbilirubinemia (jaundice), hematomas and disorders of the blood microcirculation. [0004] Whether extrinsic or intrinsic, those factors induce cosmetically undesirable impairment of the visible appear- ance, clinical and physical properties and physiological and histological functions of the skin and even give rise to visible signs of (premature or non-premature) aging of the skin. [0005] The most noteworthy and patent changes include dryness and the development of fine lines and wrinkles, loss 25 of elasticity, wasting and sagging of the skin, loss of firmness, thinning of the skin, loss of uniformity of the complexion, a dull complexion, hyperpigmentation, senile lentigines, red spots, a rough, coarse surface texture and a marbled pig- mentation. Dull and impaired hair, hair loss and an unbalanced scalp are also frequent symptoms. [0006] Other less obvious but nonetheless measurable changes occur when the skin ages or is subject to chronic environmental aggression and include a general reduction in the vitality of the tissues and cells, slowed cell replication, 30 a decrease in protein synthesis, an increase in proteolysis, a decrease in cutaneous blood circulation or vasodilatation with blood stasis, seepage from the blood compartment, reduced water content, an accumulation of errors in the structure and function of proteins, a deleterious change in the skin’s barrier properties, connective tissues and cohesion, and a reduced ability of the skin to remodel and repair itself. [0007] In particular, in the case of secondary effects related to accumulation of iron in the peripheral cutaneous tissues, 35 such as hyperbilirubinemia (jaundice, neonatal icterus), hematoma, and rings (or circles) under the eyes, pigmentation is promoted by the inadequate elimination of hemolysis products: violet-green appearance of biliverdin, brown-red- orange with bilirubin and mineral iron, violet with hemosiderin. [0008] For many people, an impaired or aged skin reminds them of the disappearance of youth. For that reason, our societies attribute great importance to apparent youth and fighting against deteriorated/damaged/imperfect skin has 40 become an economic issue. The treatments proposed range from functional cosmetic creams to cosmetic surgery. [0009] External factors, like internal factors, supply the body with a great variety of substances that are both exogenous (xenobiotics) and endogenous. Those substances, frequently lipophilic, have a high affinity for the skin that is itself lipid- based. The skin surface concentrates all the substances that impair the skin and contribute to its imperfection. [0010] WO2004/089392 discloses a composition comprising a mixture of two specific classes of compounds, Free- 45 B-Ring flavonoids and flavans, for use in the prevention and treatment of diseases and conditions associated with the skin. This composition simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity in normal, aged and damaged dermal cells and tissues. A formulation called Soliprin™ is disclosed comprising chrysin and chrysin-7-glucuronide among a mixture of Free-B-Ring flavonoids. In one proposed embodiment, the Free-B-Ring flavonoids are combined with a chelating agent (for example ETDA). 50 [0011] WO2004/030605 discloses a cosmetic cream comprising an extract of Prunus domestica containing chrysin and EDTA-4Na as chelator. [0012] EP1201227 discloses a sunscreen formulation comprising an extract of passion flower containing chrysin and/or analogs and Na3H-EDTA as chelator. 55 BRIEF SUMMARY OF THE INVENTION [0013] We have now discovered that the essential characteristics of deteriorated/imperfect skin are frequently the presence of xenobiotics and/or the abnormal accumulation of endogenous substances. In consequence, the use of at 3 EP 1 776 161 B1 least one UGT-inducer could enable a preventive and/or curative effect on deteriorated/imperfect skin to be obtained. [0014] We have also demonstrated the presence of UGT enzymes in the human skin. Stimulation of those cutaneous enzymes has been tested and the topical use of an UGT-inducer to protect the skin and/or enhance its state is proposed. The applicant has discovered that topical application of a UGT-inducer stimulates the expression of those enzymes. 5 [0015] Many compounds have been described as being useful for improving
Load more

Recommended publications
  • A Monitoring of Allantoin, Uric Acid, and Malondialdehyde Levels In
    A Monitoring of Allantoin, Uric Acid, and Malondialdehyde Levels in Plasma and Erythrocytes after a 10-Minute Running Activity ROMAN KANĎÁR, XENIE ŠTRAMOVÁ, PETRA DRÁBKOVÁ, JANA KŘENKOVÁ Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic A running title: Allantoin and Uric Acid Levels after Running Activity Correspondence to: Roman Kanďár, Ph.D., Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic Tel.: +420 466037714 Fax: +420 466037068 E-mail: [email protected] Keywords: allantoin, uric acid, oxidative stress, antioxidants, short-term intense exercise 1 Summary Uric acid is the final product of human purine metabolism. It was pointed out that this compound acts as an antioxidant and is able to react with reactive oxygen species forming allantoin. Therefore, the measurement of allantoin levels may be used for the determination of oxidative stress in humans. The aim of the study was to clarify the antioxidant effect of uric acid during intense exercise. Whole blood samples were obtained from a group of healthy subjects. Allantoin, uric acid, and malondialdehyde levels in plasma and erythrocytes were measured using a HPLC with UV/Vis detection. Statistical significant differences in allantoin and uric acid levels during short-term intense exercise were found. Immediately after intense exercise, the plasma allantoin levels increased on the average of two hundred per cent in comparison to baseline. Plasma uric acid levels increased slowly, at an average of twenty per cent. On the other hand, there were no significant changes in plasma malondialdehyde.
    [Show full text]
  • Allantoin-Hydrolyzed Animal Protein Product
    Patentamt JEuropaischesEuropean Patent Office ® Publication number: 0 087 374 Office européen des brevets B1 (Î2) EUROPEAN PATENT SPECIFICATION (45) Dateof publication of patent spécification: 27.05.87 ® Int. Cl.4: A 23 J 3/00, A 61 K 7/48 (§) Application number: 83400376.6 (22) Date of filing: 23.02.83 (54) Allantoin-hydrolyzed animal protein product. (30) Priority: 24.02.82 US 351722 (73) Proprietor: CHARLES OF THE RITZ GROUP LTD. 01.06.82 US 383404 40 West 57th Street 13.12.82 US 449117 New York, NY 10019 (US) (§) Dateof publication of application: (72) Inventor: Puchalski, Eugène 31.08.83 Bulletin 83/35 129 McAdoo Avenue Jersey City New Jersey (US) Inventor: Deckner, George E. (§) Publication of the grant of the patent: 645 Horst Street 27.05.87 Bulletin 87/22 Westfield New Jersey (US) Inventor: Dixon, Richard P. 23 Avondale Lane (§) Designated Contracting States: Aberdeen New Jersey (US) AT BE CH DE FR GB IT Ll LU NL SE Inventor: Donahue, Frances A. 2 Kimberley Court Apt. 16 Middletown New Jersey (US) (58) Références cited: FR-A-2510 563 Y- US-A-3 941722 (74) Représentative: Maiffret, Bernard et al Cû Law Offices of William J. Rezac 49, avenue SOAP, PERFUMERY AND COSMETICS, vol. 49, Franklin D. Roosevelt no. 11, November 1976, pages 481-485. S. B. F-75008 Paris (FR) ^ MECCA: "Uric acid, allantoin and allantoin ^ derivatives" SE1FEN- OLE - FETTE - WACHSE, vol. 97, no. 15, N 1971, pages 533-534. S. B. MECCA: "Neue 00 Allantoin-Derivate fur die kosmetische und O dermatologische Anwendung" C9 Note: Within nine months from the publication of t\the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposopposition to the European patent granted.
    [Show full text]
  • Identification of Compounds That Rescue Otic and Myelination
    RESEARCH ARTICLE Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant Elvira Diamantopoulou1†, Sarah Baxendale1†, Antonio de la Vega de Leo´ n2, Anzar Asad1, Celia J Holdsworth1, Leila Abbas1, Valerie J Gillet2, Giselle R Wiggin3, Tanya T Whitfield1* 1Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; 2Information School, University of Sheffield, Sheffield, United Kingdom; 3Sosei Heptares, Cambridge, United Kingdom Abstract Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also results in defects in the inner ear: otic tissue fails to down-regulate versican gene expression and morphogenesis is disrupted. We have designed a whole-animal screen that tests for rescue of both up- and down-regulated gene expression in mutant embryos, together with analysis of weak and strong alleles. From a screen of 3120 structurally diverse compounds, we have identified 68 that reduce versican b expression in the adgrg6 mutant ear, 41 of which also restore myelin basic protein gene expression in Schwann cells of mutant embryos. Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates for molecules that may interact directly with the Adgrg6 receptor. Our pipeline provides a powerful approach for identifying compounds that modulate GPCR activity, with potential impact for future drug design. DOI: https://doi.org/10.7554/eLife.44889.001 *For correspondence: [email protected] †These authors contributed Introduction equally to this work Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in Langenhan et al., Competing interest: See 2016; Patra et al., 2014).
    [Show full text]
  • The Use of Animal Models in Diabetes Research
    Journal of Analytical & Pharmaceutical Research A Comprehensive Review: The Use of Animal Models in Diabetes Research Abstract Review Article Diabetes, a lifelong disease for which there is no cure yet. It is caused by reduced Volume 3 Issue 5 - 2016 production of insulin, or by decreased ability to use insulin. With high prevalence of diabetes worldwide, the disease constitutes a major health concern. Presently, it is an incurable metabolic disorder which affects about 2.8% of the global Iksula Services Pvt. Ltd, India population. Fifty percent of all people with Type I diabetes are under the age of 20. Insulin-dependent diabetes accounts for 3% of all new cases of diabetes *Corresponding author: Reena Rodrigues, Iksula Services each year. Hence, the search for compounds with novel properties to deal Pvt. Ltd, Mumbai, Maharashtra, India, Tel: 022-25924504; with this disease condition is still in progress. Due to time constrains, the use Email: of experimental models for the disease gives the necessary faster. The current review has attempted to bring together all the reported models, highlighted their Received: November 14, 2016 | Published: December 12, short comings and drew the precautions required for each technique. In Type 1 2016 or Diabetes mellitus, the body is unable to store and use glucose as an energy source effectively. Type 2 or diabetes insipidus is a heterogeneous disorder. In this review article we shall bring light as to how hyperglycemia, glucosuria and hyperlipidemia play an important role in the onset of diabetes. Keywords: Diabetes mellitus; Hyperglycemia; Diabetes insipidus; insulin Abbreviations: STZ: Streptozotocin; DNA: Deoxyribonucleic Acid; NAD: Nicotinamide Adenine Dinucleotide; GTG: Gold research.
    [Show full text]
  • Determination of the Major Flavonoid from Qina (Eucalyptus Globules L.) Using Shift Reagent, UV and IR Spectrophotometry
    Determination Of The Major Flavonoid From Qina (Eucalyptus globules L.) Using Shift Reagent, UV And IR Spectrophotometry. BY Leni Ali Edris Adam B.Sc. Science and Education, El-Zeim Alazhari University( 2003) Postgraduate Diploma in Applied Chemistry, Gezira University( 2009) A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in Chemistry Department of Applied Chemistry and Chemical Technology Faculty of Engineering and Technology Supervisor: Prof.Mohamed Abdel Karim Mohamed Co-supervisor:Dr. Mohamed Osman Babiker October -2012 ~1~ Determination Of The Major Flavonoid From Qina (Eucalyptus globules L.) Using Shift Reagent, UV And IR Spectrophotometry. BY Leni Ali Edris Adam Examination Committee: Name Position Signature Prof.Mohamed Abdel Karim Mohame Chairperson ................. Dr. Abo Bakr Khidir Ziada Intarnal Examiner …………. Dr. Abd Elsalam Abdalla Dafa Alla Extarnal Examiner …….. Date OF Examination: 6\10\2012 ~2~ Dedication This work is dedicated to My father who Deserved all respect, my mother For her care and passion, my husband for his help and support, my family and Friends. ~3~ Acknowledgements I thank Allah, Almighty for help. I wish to express my deep gratitude to my supervisor Prof. Mohamed Abdel Karim Mohamed for supervision and advice. I am grateful to all those who helped me to finish this thesis. My thanks are also extended to my colleagues for kind support. ~4~ Abstract Qina bark (Eucalyptus globules.L) is used in ethnomedicine as anti- inflammatory and antimalarial remedy.This study was aimed to extract and determine the physiochemical properties of the major flavonoid of quina bark. The plant material was collected from northern Kordofan and extracted with ethanol.
    [Show full text]
  • Film Dressings Based on Hydrogels: Simultaneous and Sustained-Release of Bioactive Compounds with Wound Healing Properties
    pharmaceutics Article Film Dressings Based on Hydrogels: Simultaneous and Sustained-Release of Bioactive Compounds with Wound Healing Properties 1, 2,7, 3 2,7 Fabian Ávila-Salas y, Adolfo Marican y, Soledad Pinochet , Gustavo Carreño , Oscar Valdés 3 , Bernardo Venegas 4, Wendy Donoso 4, Gustavo Cabrera-Barjas 5 , Sekar Vijayakumar 6 and Esteban F. Durán-Lara 7,8,* 1 Centro de Nanotecnología Aplicada, Facultad de Ciencias, Universidad Mayor, Huechuraba 8580000, Región Metropolitana, Chile 2 Instituto de Química de Recursos Naturales, Universidad de Talca, Talca 3460000, Maule, Chile 3 Vicerrectoría de Investigación y Postgrado, Universidad Católica del Maule, Talca 3460000, Maule, Chile 4 Department of Stomatology, Faculty of Health Sciences, University of Talca, Talca 3460000, Chile 5 Technological Development Unit (UDT), Universidad de Concepción, Av. Cordillera 2634, Parque Industrial Coronel, Coronel 4191996, Biobío, Chile 6 Nanobiosciences and Nanopharmacology Division, Biomaterials and Biotechnology in Animal Health Lab, Department of Animal Health and Management, Alagappa University, Science Campus 6th Floor, Karaikudi-630004, Tamil Nadu, India 7 Bio and NanoMaterials Lab, Drug Delivery and Controlled Release, Universidad de Talca, Talca 3460000, Maule, Chile 8 Departamento de Microbiología, Facultad de Ciencias de la Salud, Universidad de Talca, Talca 3460000, Maule, Chile * Correspondence: [email protected]; Tel.: +56-71-2200363 These authors contributed equally to this work. y Received: 30 July 2019; Accepted: 26 August 2019; Published: 2 September 2019 Abstract: This research proposes the rational modeling, synthesis and evaluation of film dressing hydrogels based on polyvinyl alcohol crosslinked with 20 different kinds of dicarboxylic acids. These formulations would allow the sustained release of simultaneous bioactive compounds including allantoin, resveratrol, dexpanthenol and caffeic acid as a multi-target therapy in wound healing.
    [Show full text]
  • Allantoin a Safe and Effective Skin Protectant
    Allantoin A safe and effective skin protectant 1. Overview Allantoin, as a natural compound derived from Symphytum officinale, has long been known for its beneficial effects on skin. It is an active compound with keratolytic, keratoplastic, soothing and healing properties largely used in cosmetic, topical pharmaceutical and veterinary products. Allantoin is an anti-irritating and non-toxic agent listed in United States Pharmacopeia, European Pharmacopoeia, Merck Index and British Pharmacopoeial Codex. FDA recognizes allantoin as a skin protectant active ingredient for over-the-counter (OTC) human use. 2. Chemical structure Structural formula: H O O N H H O N N N H H H Empirical formula: C4H6N4O3 Molecular weight: 158.12 Info ALLANTOIN.doc 1/13 02/03/06 Version 04 3. Codex and names CTFA/JSCI name: Allantoin INCI name: Allantoin EINECS name Urea, (2,5-Dioxo-4-Imidazolidinyl)- CAS number: [97-59-6] EINECS number: 202-592-8 JSCI number: S0016 4. Specifications data Appearance: powder Colour: white Odour: odourless Identification: corresponds to C.T.F.A. IR spectrum Assay: 99.0% min Nitrogen: 35.0% – 35.5% pH (0.5% water solution): 3.5 – 6.5 Loss on drying: 0.2% max Sulphated ash: 0.1% max Sulphate: 200 ppm Chloride: 50 ppm Heavy metals (Pb): less than 10 ppm Glycoluril: less than 0.2% Total viable count: Less than 1000 cfu/g Shelf life: 5 year in original packing The analytical methods are available on request. 5. General description Allantoin is a functional compound with mild keratolytic and keratoplastic action on skin. Although the biochemical mechanism of its keratolytic action has not been yet determined, allantoin soften and loosen keratin by disrupting its structure, thereby facilitating desquamation of the cornified cells on the top layer of skin.
    [Show full text]
  • GRAS Notice (GRN) No. 719, Orange Pomace
    GRAS Notice (GRN) No. 719 https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm SAFETY EVALUATION DOSSIER SUPPORTING A GENERALLY RECOGNIZED AS SAFE (GRAS) CONCLUSION FOR ORANGE POMACE SUBMITTED BY: PepsiCo, Inc. 700 Anderson Hill Road Purchase, NY 10577 SUBMITTED TO: U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food Additive Safety HFS-200 5100 Paint Branch Parkway College Park, MD 20740-3835 CONTACT FOR TECHNICAL OR OTHER INFORMATION: Andrey Nikiforov, Ph.D. Toxicology Regulatory Services, Inc. 154 Hansen Road, Suite 201 Charlottesville, VA 22911 July 3, 2017 Table of Contents Part 1. SIGNED STATEMENTS AND CERTIFICATION ...........................................................1 A. Name and Address of Notifier .............................................................................................1 B. Name of GRAS Substance ...................................................................................................1 C. Intended Use and Consumer Exposure ................................................................................1 D. Basis for GRAS Conclusion ................................................................................................2 E. Availability of Information ..................................................................................................3 Part 2. IDENTITY, METHOD OF MANUFACTURE, SPECIFICATIONS, AND PHYSICAL OR TECHNICAL EFFECT.................................................................................................4
    [Show full text]
  • (Piper Nigrum L.) Products Based on LC-MS/MS Analysis
    molecules Article Nontargeted Metabolomics for Phenolic and Polyhydroxy Compounds Profile of Pepper (Piper nigrum L.) Products Based on LC-MS/MS Analysis Fenglin Gu 1,2,3,*, Guiping Wu 1,2,3, Yiming Fang 1,2,3 and Hongying Zhu 1,2,3,* 1 Spice and Beverage Research Institute, Chinese Academy of Tropical Agricultural Sciences, Wanning 571533, China; [email protected] (G.W.); [email protected] (Y.F.) 2 National Center of Important Tropical Crops Engineering and Technology Research, Wanning 571533, China 3 Key Laboratory of Genetic Resources Utilization of Spice and Beverage Crops, Ministry of Agriculture, Wanning 571533, China * Correspondence: [email protected] (F.G.); [email protected] (H.Z.); Tel.: +86-898-6255-3687 (F.G.); +86-898-6255-6090 (H.Z.); Fax: +86-898-6256-1083 (F.G. & H.Z.) Received: 16 July 2018; Accepted: 7 August 2018; Published: 9 August 2018 Abstract: In the present study, nontargeted metabolomics was used to screen the phenolic and polyhydroxy compounds in pepper products. A total of 186 phenolic and polyhydroxy compounds, including anthocyanins, proanthocyanidins, catechin derivatives, flavanones, flavones, flavonols, isoflavones and 3-O-p-coumaroyl quinic acid O-hexoside, quinic acid (polyhydroxy compounds), etc. For the selected 50 types of phenolic compound, except malvidin 3,5-diglucoside (malvin), 0 L-epicatechin and 4 -hydroxy-5,7-dimethoxyflavanone, other compound contents were present in high contents in freeze-dried pepper berries, and pinocembrin was relatively abundant in two kinds of pepper products. The score plots of principal component analysis indicated that the pepper samples can be classified into four groups on the basis of the type pepper processing.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,227,164 Lundmark 45 Date of Patent: Jul
    USOO522.7164A United States Patent (19) 11 Patent Number: 5,227,164 Lundmark 45 Date of Patent: Jul. 13, 1993 54 HAIR TREATMENT COMPOSITION AND 3,954,989 5/1976 Mecca ................................. 424/273 METHOD 3,970,756 7/1976 Mecca ................................. 424/273 4,220,166 9/1980 Newell .................................... 132/7 76 Inventor: Larry D. Lundmark, 2925 84th Ave. 4,220,167 9/1980 Newell .................................... 132/7 North, Brooklyn Park, Minn. 55444 4,296,763 10/981 Priest et al. ............................ 132/7 4,478,853 10/1984 Chaussee ...... ... 424/358 (21) Appl. No.: 743,739 4,514,338 4/1985 Hanck et al. 260/429.9 1ar. 4,602,036 7/1986 Hanck et al. ... 54/494. 22 Filed: Aug. 12, 1991 4,705,681 1/1987 Maes et al. ............................ 424/70 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation of Ser. No. 471,843, Jan. 29, 1990, Pat. 1117539 2/1982 Canada ..............................., 514/390 No. 5,041,285. OTHER PUBLICATIONS 51 int. Cli.............................................. A61K 7/021 w 52 U.S. C. ...................................... 424/401; 424/65; Panthenol in Cosmetics, Ibson Drug & Cosmetic Indus 424/68; 424/70 try 5 pp. May 1974. 58) Field of Search ..................... 424/65, 68, 70,401; Urigacid Allantoin and Allantoin Derivatives Soap 548/105, 308, 311, 318.1; 562/569;564/503, Perfumery and Cosmetics, Mecca Reprint Oct. and (56) References Cited Nov. 1976 Issues. Parts 1 & 2 11 pp. Primary Examiner-Thurman K. Page U.S. PATENT DOCUMENTS Assistant Examiner-D. Colucci 2,761,867 9/1956 Mecca ................................. 260/299 2,898,373 8/1959 Kaul ...............
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
    [Show full text]
  • Relation Structure/Activité De Tanins Bioactifs Contre Les Nématodes
    En vue de l'obtention du DOCTORAT DE L'UNIVERSITÉ DE TOULOUSE Délivré par : Institut National Polytechnique de Toulouse (INP Toulouse) Discipline ou spécialité : Pathologie, Toxicologie, Génétique et Nutrition Présentée et soutenue par : Mme JESSICA QUIJADA PINANGO le jeudi 17 décembre 2015 Titre : RELATION STRUCTURE/ACTIVITE DE TANINS BIOACTIFS CONTRE LES NEMATODES GASTROINTESTINAUX (HAEMONCHUS CONTORTUS) PARASITES DES PETITS RUMINANTS Ecole doctorale : Sciences Ecologiques, Vétérinaires, Agronomiques et Bioingénieries (SEVAB) Unité de recherche : Interactions Hôtes - Agents Pathogènes (IHAP) Directeur(s) de Thèse : M. HERVÉ HOSTE Rapporteurs : M. ADIBE LUIZ ABDALLA, UNIVERSIDAD DE SAO PAULO Mme HEIDI ENEMARK, NORWEGIAN VETERINARY INSTITUTE Membre(s) du jury : 1 M. FRANÇOIS SCHELCHER, ECOLE NATIONALE VETERINAIRE DE TOULOUSE, Président 2 M. HERVÉ HOSTE, INRA TOULOUSE, Membre 2 Mme CARINE MARIE-MAGDELAINE, INRA PETIT BOURG, Membre 2 M. SMARO SOTIRAKI, HAO-DEMETER, Membre 2 M. VINCENT NIDERKORN, INRA CLERMONT FERRAND, Membre QUIJADA J. 2015 Cette thèse est dédiée à mes parents, Teresa et Héctor, À mon mari, Rafäel, pour son soutien inconditionnel, son amour illimité, sa patience, sa loyauté, son amitié et surtout sa confidence, À ma grand-mère, Marcolina, car m'ait donné le plus grand et précieux cadeau en ma vie : ma foi en Dieu ma forteresse et mon espoir (Isaïas 41:13). À mes adorés sœurs, belle- sœurs et frère : Yurlin, Indira, Iskay, Olga, Zoraida et Jesus. Merci pour l’amour infini que m’ont toujours été donné, celui qu’a été prolongé par l'amour de mes merveilleux neveux. 1 QUIJADA J. 2015 REMERCIEMENTS Je remercie tout d’abord mon Dieu pour me donner le cadeau de la vie, et la forteresse pour vivre chaque jour.
    [Show full text]